BioNTech Presents Phase 1/2 Data Update For CAR-T Cell Therapy Candidate BNT211 In Advanced Solid Tumors At ESMO Congress 2023
Portfolio Pulse from Benzinga Newsdesk
BioNTech has presented Phase 1/2 data for its CAR-T cell therapy candidate BNT211 at the ESMO Congress 2023. The therapy, which targets the oncofetal antigen Claudin-6 (CLDN6), has shown encouraging antitumor activity in patients with CLDN6-positive relapsed or refractory advanced solid tumors. The overall response rate was 59% and the disease control rate was 95%.
October 23, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNTech's BNT211 therapy has shown promising results in Phase 1/2 trials, potentially leading to increased investor confidence in the company.
The positive results from the Phase 1/2 trials of BioNTech's BNT211 therapy could lead to increased investor confidence in the company's ability to develop effective treatments. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100